Seer Reports Modest Revenue Growth Amid Budgetary Pressures
Event summary
- Seer reported $16.6 million in full-year 2025 revenue, up 17% YoY, with Q4 revenue at $4.2 million, a 5% increase.
- Installed base grew 67% YoY to 82 instruments, with 33 new installations in 2025.
- Net loss narrowed to $73.6 million for 2025 from $86.6 million in 2024.
- 2026 revenue guidance set at $16 million to $18 million, a 3% midpoint growth.
- Cash position stood at $240.6 million as of December 31, 2025.
The big picture
Seer's 2025 results reflect the challenges of operating in a budget-constrained environment, particularly in the biotech sector where funding fluctuations are common. The company's strategic focus on expanding its installed base and consumable kit sales aligns with broader industry trends toward scalable proteomic solutions. The modest revenue growth and narrowing net loss indicate progress, but the ability to convert scientific validation into sustained commercial success remains a critical test.
What we're watching
- Revenue Growth
- Whether Seer can sustain revenue growth amid persistent budgetary pressures, particularly from NIH funding uncertainty.
- Operational Efficiency
- The pace at which Seer can reduce operating expenses while maintaining R&D and commercial momentum.
- Market Adoption
- How the expansion of the installed base and consumable kit volume will impact long-term customer retention and revenue stability.
Related topics